Healthcare >> CEO Interviews >> July 5, 2004
MICHAEL M. WICK is Chairman and Chief Executive Officer of Telik, Inc.
He joined Telik in 1997 from CV Therapeutics, Inc. where he was Senior
Vice President of Research and Development. Prior to joining CV
Therapeutics, Dr. Wick was Executive Director of Oncology/Immunology and
Clinical Research at Lederle Laboratories, a division of American
Cyanamid, where he also directed the Cyanamid/Immunex joint oncology
research program. Dr. Wick began his career at Harvard Medical School,
where he was an Associate Professor. He also was Chief of the Melanoma
Clinic and Laboratory of Molecular Dermatological Oncology at the Dana
Farber Cancer Institute. Dr. Wick holds a PhD degree in Chemistry from
Harvard University and an MD degree from Harvard Medical School. Profile
Dr. Wick: Telik is a biotechnology company focused on cancer drug
discovery and development. We have used our TRAP computational
